Related content

Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor

By Chung Francisco   Wang Liang-Chuan   Kestell Philip   Baguley Bruce   Ching Lai-Ming  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 5, 2004-05 ,pp. : 377-383

Springer Publishing Company

Access to resources Recommend Favorite

Fundamental, Electron Transfer Mechanism by Pyrylium-Type Ions for the Anticancer Drugs 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) and Flavone-8-Acetic Acid (FAA)

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 5, Iss. 5, 2005-09 ,pp. : 501-506

Bentham Science Publishers

Access to resources Recommend Favorite

NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Woon S.-T.   Zwain S.   Schooltink M.A.   Newth A.L.   Baguley B.C.   Ching L.-M.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1176-1183

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

By Jameson M.   Baguley B.   Kestell P.   Zhao L.   Paxton J.   Thompson P.   Waller S.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor

By Pang J.-H.   Cao Z.   Joseph W.R.   Baguley B.C.   Ching L.-M.  

European Journal of Cancer, Vol. 34, Iss. 8, 1998-07 ,pp. : 1282-1289

Elsevier

Access to resources Recommend Favorite